Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

Press Release

  • 26 September 2023
    Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
  • 22 August 2023
    Infographic | HitGen FY2023 Half-Year Report
  • 10 August 2023
    HitGen Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics
  • 26 June 2023
    HitGen launches a newly upgraded version of OpenDEL™, a self-service screening kit, to facilitate innovative drug discovery research
  • 18 May 2023
    HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics
  • 28 April 2023
    Infographic | HitGen FY2022 Annual Report
Read More

Coverage

  • July 15, 2020

    Jin LI – Chairman & CEO, HitGen, China

    PHARMA BOARDROOM Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion. "By now, we have a platform of over 500 billion small molecules, and in terms of published numbers, we probably have the largest DEL collections in the world. By the end of this year, we hope to have built a DEL of over one trillion small molecules!"
  • May 07, 2020

    New economy business becomes a growing driver of city development

    China Daily, Yuan Shenggao 2020-05-07 HitGen, a local biopharmaceutical company, was listed on the science and technology innovation board at the Shanghai Stock Exchange in mid-April, and is the first company in southwestern China to appear on the board. The company, founded in 2012, provides research services for the early stages of drug discovery using its core DNA encoded compound library technology. It has established partnerships with multinational drug and biomedicine companies such as Pfizer, Johnson & Johnson, MSD and Sanofi. Li Jin, chairman and general manager of HitGen, said it will expand investment into DNA encoded compound library technology and business, to promote research and development of drugs.
  • April 29, 2020

    Chinese biotech firm uses DNA to discover new drugs

    CGTN, By Wei Lynn Tang HitGen Inc., a Chengdu-based biotechnology company that has listed on China's Science and Technology Innovation Board on April 16, raising some 118 million U.S. dollars. According to the company's listing prospectus, 75 percent of its listing net proceeds will be used for a new molecular design, construction, and application platform construction project, with the remaining funds for a new drugs research and development project. According to the company's listing prospectus, 75 percent of its listing net proceeds will be used for a new molecular design, construction, and application platform construction project, with the remaining funds for a new drugs research and development project. Li Jin, chairman and CEO of HitGen, said the company's top priority is to continue to invest in its core technology – the DEL technology – to make progress in its drug discovery programs.
Read More

Events

November 03-January 01
See you in Shanghai! HitGen Pharmaceuticals Inc. to attend the 5th China International Import Expo
January 11-01
Meet us in BIOTECH SHOWCASE™2022 in virtual!
June 10-18
BIO International Digital Convention 2021
May 18-20
Drug Discovery Chemistry
January 12-01
Meet you in JPM 2022
June 30-30
Webinar: Advancing Innovative Drug Discovery by DNA Encoded Library (DEL) and FBDD/SBDD methods
June 09-21
BIO KOREA 2021
Read More

Industry News

  • 09.13
    DEL for Enzymes with Specific Mode of Action (MoA)
    Enzymes are arguably the most ideal targets for small molecule drugs, owing to their involvement in chemical reaction catalysis and the better ligandability of the binding pockets.
  • 08.25
    DEL for Protein-Protein Interaction
    Protein-protein interactions (PPI) are physical and chemical contacts between two or more protein molecules. As a fundamental aspect of almost all biological processes, any interference of the sophisticated PPI network could result in potential physiological disorder or disease.
  • 08.15
    DEL for RNA
    While proteins have traditionally been the primary target class for drug discovery, the landscape is rapidly evolving.
  • 08.07
    DEL for DNA- and RNA-Binding Proteins
    While DNA-encoded library (DEL) selection has been applied to a variety of targets with multiple candidates progressed into different stages of drug development, the utilization of DEL in DNA- and RNA-binding proteins remains questionable. This is largely due to the fact that each DEL compound contains a long stretch of DNA barcode, which when used to screen against DNA- or RNA- binding proteins (transcription factors, DNA polymerases, helicases, DNases, RNases, chromatin modifying complexes, etc.) , would lead to significant false positives.
Read More

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects
验证码
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information